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Long-term results of a multicenter randomized
study on direct versus crossover bypass for
unilateral iliac artery occlusive disease
Jean-Baptiste Ricco, MD, PhD,a and Hervé Probst, MD, PhD,b on behalf of the French University
Surgeons Association (AURC), Poitiers, France; and Lausanne, Switzerland
Objective: To compare late patency after direct and crossover bypass in good-risk patients with unilateral iliac occlusive
disease not amenable to angioplasty.
Methods: Between May 1986 and March 1991, 143 patients with unilateral iliac artery occlusive disease and disabling
claudication were randomized into two surgical treatment groups, ie, crossover bypass (n 74) or direct bypass (n 69).
The size of the patient population was calculated to allow detection of a possible 20% difference in patency in favor of
direct bypass with a one-sided alpha risk of 0.05 and a beta risk of 0.10. Patients underwent yearly follow-up
examinations using color flow duplex scanning with ankle-brachial systolic pressure index measurement. Digital
angiography was performed if hemodynamic abnormalities were noted. Median follow-up was 7.4 years. Primary
endpoints were primary patency and assisted primary patency estimated by the Kaplan-Meier method with 95%
confidence interval. Secondary endpoints were secondary patency and postoperative mortality and morbidity.
Results: Cardiovascular risk factors, preoperative symptoms, iliac lesions TASC class (C in 87 [61%] patients and D in 56
[39%] patients), and superficial femoral artery (SFA) run-off were comparable in the two treatment groups. One patient
in the direct bypass group died postoperatively. Primary patency at 5 years was higher in the direct bypass group than in
the crossover bypass group (92.7  6.1% vs 73.2  10%, P  .001). Assisted primary patency and secondary patency at
5 years were also higher after direct bypass than crossover bypass (92.7 6.1% vs 84.3 8.5%, P .04 and 97.0 3.0%
vs 89.8  7.1%, P  .03, respectively). Patency at 5 years after crossover bypass was significantly higher in patients
presenting no or low-grade SFA stenosis than in patients presenting high-grade (>50%) stenosis or occlusion of the SFA
(74.0  12% vs 62.5  19%, P  .04). In both treatment groups, patency was comparable using polytetrafluoroethylene
(PTFE) and polyester grafts. Overall survival was 59.5  12% at 10 years.
Conclusion: This study showed that late patency was higher after direct bypass than crossover bypass in good-risk patients
with unilateral iliac occlusive disease not amenable to angioplasty. Crossover bypass should be reserved for high-risk
patients with unilateral iliac occlusion not amenable to percutaneous recanalization. (J Vasc Surg 2008;47:45-54.)Crossover femorofemoral bypass described by Freeman
and Leeds1 in 1952 was first used as an alternative to direct
aortofemoral bypass in high-risk patients with critical isch-
emia due to unilateral iliac artery occlusive disease.2 Having
since gained broad acceptance, crossover bypass is now
widely used to treat complex vascular problems associated
with failed aortofemoral bypass or unilateral long-segment
iliac occlusion graded TASC-C or –D.3 Unilateral iliac
artery stenosis graded TASC-A or -B is now treated by
angioplasty. Outcome of crossover bypass has varied widely
in published series. The most likely explanation for this
variability involves patient selection. Some authors use
crossover bypass exclusively for high-risk patients with limb
threatening ischemia while others extend indications to
low-risk patients with claudication. Investigators using ex-
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with 5-year patency rates ranging from 82% to 90%.4-6
Variation in outcome has led to confusion regarding
the utility of crossover bypass in comparison to direct
bypass and the impact on late patency of variables such as
the donor iliac artery disease,7 femoral artery run-off, and
type of graft material.8-10 To gain more insight into these
issues, the French University Surgeons Association (French
acronym, AURC) undertook a multicenter randomized
trial11 to compare the patency and safety of crossover
bypass and direct bypass in good-risk patients with symp-
tomatic unilateral iliac occlusive disease not amenable to
endovascular treatment. The purpose of this report is to
describe long-term follow-up results of that trial.
PATIENTS AND METHODS
This prospective multicenter trial comparing direct
and crossover bypasses was conducted fromMay 1986 to
March 1991 at 20 hospitals in France (see list in Appen-
dix, online only). The study design was approved by the
ethics committee of the University Hospital of Poitiers,
and all patients provided written informed consent. Ran-
dom assignment of patients to the two treatment groups
was done independently of participating centers in a
one-to-one ratio. The randomization sequence was gen-
45
JOURNAL OF VASCULAR SURGERY
January 200846 Ricco and Probsterated by a computer program and supplied to centers
using sealed opaque envelopes generated in blocks of
five.
Endpoints. Primary endpoints were primary patency
and assisted primary patency. Secondary endpoints were
secondary patency and postoperative morbidity and mor-
tality. This study used a strict definition for primary paten-
cy12 that included persistent patency without repeat inter-
vention not only on the bypass and its anastomoses but also
on the donor iliac artery of crossover bypasses. Assisted
primary patency was defined as patency achieved with mi-
nor reintervention including dilation or anastomotic revi-
sion to prevent graft failure. Secondary patency was defined
as patency obtained by restoration after occlusion. In this
study, choice of prosthetic graft with regard to material,
external support, and diameter was not randomized and left
to the discretion of the surgeon.
Patient selection criteria. Patients were eligible for
inclusion if they had (1) unilateral disabling intermittent
claudication with a walking distance of less than 300meters
and significantly reduced ankle-to-brachial systolic blood
pressure index (ABI) 0.6 and (2) occlusion or diffuse
stenosis involving the common iliac artery, external iliac
artery, and/or common femoral artery considered by the
surgeon as not amenable to percutaneous angioplasty or
recanalization (Table I). An additional criterion for inclu-
sion was demonstration of normal contralateral common
and external iliac arteries on anteroposterior and oblique
angiographic views with normal duplex scan findings in-
cluding a peak systolic velocity 1.2 m/s in the common
and external iliac arteries.
Patients over the age of 75 years, presenting comorbid
conditions that impaired short-term survival or requiring
hemodialysis were excluded. Patients with general risk fac-
tors for laparotomy including resting angina, recent myo-
cardial infarction, severe obesity with a body-mass-index
35, or respiratory insufficiency defined as hypoxia 75
mmHg, hypercapnia50 mmHg at rest, and one-second
forced expiratory volume less than 50% of the calculated
value were also excluded. Finally, patients with a history of
aortofemoral or femorofemoral bypass, major abdominal
wound hernia, more than two laparotomies, or pelvic radi-
ation therapy were excluded.
Immediate postoperative assessment. Bypass pa-
tency was assessed by color flow duplex scan. Respiratory
complications were defined as either occurrence of pulmo-
nary infection or need for respiratory support longer than
24 hours. Ischemic cardiac complications were defined as
the presence of electrocardiogram (ECG) abnormalities.
Groin incisions were regularly checked to detect healing
complications including lymphocele, lymphorrea, and su-
perficial or deep infection. Duration of hospitalization was
recorded.
Late follow-up assessment. Follow-up examina-
tions were carried out at 1 month and yearly thereafter.
Outpatient visits included clinical examination with mea-
surement of walking distance and Doppler study with
determination of ABI. Angiography was performed ifhemodynamic deterioration was found, ie, 15% decrease
between two successive ABI measurements or if duplex
scanning peak systolic velocity in the graft or in the
donor iliac artery was greater than 2.5 m/s. The median
duration of follow-up was 7.4 years with 112 (78%), 82
(57%), and 20 (14%) patients being followed up 5, 7, and
10 years, respectively.
Statistical analysis. A meta-analysis of published
crossover bypass series13-16 was performed to determine
the size of the study population necessary to show a possi-
ble difference in the 3-year primary patency of 20% with a
one-sided alpha of 0.05 and beta risk of 0.10. Findings
demonstrated that the mean actuarial 3-year primary pa-
tency for crossover bypasses was 67%. Accordingly, it was
calculated that the number of patients needed to show a
3-year patency of 87%, in favor of the direct bypass, was 70
per group. Proportions, means and medians were com-
pared using the Fisher exact test or the Wilcoxon nonpara-
metric test as appropriate. Primary and secondary patency
rates were calculated using the Kaplan-Meier method with
95% confidence interval (95% CI).17 Groups were com-
pared using the log-rank test with calculation of the hazard
Table I. Baseline characteristics of patients randomized
for direct and crossover bypass
Characteristics*
Direct bypass
N  69
Crossover
bypass
N  74
P
value
Age -y (range) 54 (41-74) 55 (40-75) .89
Male sex - no of patients (%) 58 (84%) 60 (81%) .66
Vascular risk factors
Hypertension 13 (19%) 22 (30%) .17
Myocardial infarction 5 (7%) 7 (9%) .85
Diabetes 4 (6%) 10 (13%) .16
Hypercholesterolemia 11 (16%) 11 (15%) .98
Tobacco use 28 (41%) 29 (39%) .98
Body-mass-index† 28.3  4.2 28.7  3.8 .67
Preoperative symptoms
Claudication 57 (83%) 54 (73%) .50
Rest pain 9 (13%) 14 (19%) .50
Gangrene 3 (4%) 6 (8%) .50
Erectile dysfunction 5/59 (8.5%) 6/67 (8.9%) .94
Iliac lesions TASC class‡
TASC C 46 (67%) 41 (56%) .18
TASC D 23 (33%) 33 (44%) .18
SFA lesions (symptomatic
leg)§
SFA with stenosis 50% 44 (64%) 44 (59%) .59
SFA with stenosis 50%
or occluded
25 (36%) 30 (41%) .59
SFA, Superficial femoral artery.
*Proportions, means, and medians were compared using the Fisher exact
test, Student t-test, and the Wilcoxon nonparametric test, respectively.
†The body-mass-index is the weight in kilograms divided by the square of
the height in meters. Plus-minus values are means  standard deviation.
‡According to TASC II [3], TASC C: Unilateral external iliac artery (EIA)
stenosis or occlusion extending into the common femoral artery (CFA).
TASC D: Unilateral occlusion of both the common iliac artery (CIA) and
EIA or diffuse stenoses involving CIA, EIA, and CFA.ratio with 95% CI.
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Between May 1986 and March 1991, 147 patients
presenting unilateral iliac artery stenosis or occlusion were
randomized into the two treatment groups (Fig 1). The
two study groups (Table I) were comparable with regard to
vascular risk factors, preoperative symptoms, iliac artery
lesions, and superficial femoral artery (SFA) run-off.
Surgical techniques. Direct revascularization con-
sisted of unilateral aortofemoral bypass in 36 cases and
common iliac to femoral bypass in 33. These procedures
were performed through a transperitoneal approach in 26
cases and a retroperitoneal approach in 43. Distal implan-
tation was performed on either the common femoral artery
(n 45) or deep femoral artery (n 24) depending on the
extent of the femoral lesions. Five patients underwent
femoropopliteal or femorotibial bypass during the same
procedure.
Crossover revascularization consisted of femorofemo-
ral bypass in 41 cases including 28 in which the graft was
routed subcutaneously and 13 in which the graft was
routed through the Retzius space. In the remaining 33
patients, crossover bypass consisted of iliofemoral bypass
with exposure of the external iliac artery via a supra-inguinal
route and graft placement in the Retzius space. Distal
implantation was performed on the common femoral artery
Fig 1. Study flowchart. Two patients declined and one patient
was withdrawn after a severe stroke that occurred 3 days after
randomization and prior to surgery.in 46 cases and on the deep femoral artery in 28. Ninepatients underwent femoropopliteal or femorotibial by-
passes during the same procedure.
In the direct bypass group, the graft material was poly-
tetrafluoroethylene (PTFE) in 29 cases and polyester in 40.
In the crossover bypass group, the graft material was PTFE
in 53 cases and polyester in 21. Externally supported grafts
were used for crossover bypass in 30 cases. Graft diameter
was 8 mm in 102 cases, 7 mm in 35, and 6 mm in 6.
Prophylactic antibiotics and intravenous heparin therapy
(0.5 mg/kg) were routinely used before clamping in both
groups.
Postoperative complications. As shown in Table II,
general complications were more frequent after direct by-
pass (7.1%) than crossover bypass (2.6%) but the difference
was not significant (P .26, relative risk: 0.54 with 95%CI:
0.16 to 1.76). One patient in the direct bypass group died
due to myocardial infarction within the first 30 postopera-
tive days. Healing complications in the groin including one
graft infection were more frequent after crossover bypass
(13.4%) than direct bypass (4.3%) but this difference was
not significant (P  .08 relative risk: 0.32 with 95% CI:
0.09 to 1.12). Duration of hospitalization was significantly
shorter in the crossover bypass group than in the direct
bypass group. Sexual function was analyzed in 59 patients
who underwent direct bypass and in 67 patients who un-
derwent crossover bypass. Preoperative erectile dysfunction
was reported by five patients (8.5%) in the direct bypass
group and six patients (8.9%) in the crossover bypass group.
At 6 months postoperatively, erectile dysfunction was re-
ported by two patients (3.4%) in the direct group and three
patients (4.5%) in the crossover bypass group. In addition,
four patients (6.8%) in the direct group reported postoper-
ative ejaculatory disorder (Table II).
Primary patency. Primary patency rates at 5 and 10
years were 71.8% and 55.6%, respectively in the crossover
bypass group compared with 92.7% and 82.9%, respectively
in the direct bypass group (Fig 2). These differences were
significant (P .001, hazard ratio: 4.1 with 95% CI: 1.8 to
6.7). The 30 primary graft failures in the crossover bypass
group were due to occlusion of the crossover bypass in 14
cases, stenosis of the femoral anastomosis in four, and
stenosis of the donor iliac artery in 12. The eight primary
graft failures in the direct bypass group were due to graft
occlusion in six cases and stenosis of the femoral anastomo-
sis in two. In the direct bypass group, 14 patients (20.2%)
developed significant stenosis of the contralateral iliac ar-
tery requiring angioplasty in six and crossover bypass in
two. These procedures did not affect patency of the direct
bypass.
Assisted primary patency and secondary patency.
Assisted primary patency rates at five and 10 years were
84.3% and 74.8%, respectively in the crossover bypass
group compared with 92.7% and 86.1%, respectively in the
direct bypass group (Fig 3). These differences were signif-
icant (P  .04, hazard ratio: 2.5 with 95% CI: 1.1 to 5.8).
Secondary patency rates at five and 10 years were
89.8% and 82.9%, respectively in the crossover bypass
group vs 97.0% and 94.9%, respectively in the direct
confi
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(P  .03, hazard ratio: 3.7 with 95% CI: 1.1 to 9.8). As
shown in Fig 5, all primary crossover bypass graft failures
Fig 2. Primary patency of 69 direct (D) and 74 crossover (C)
bypass procedures analyzed according to the Kaplan-Meier
method. The number of patients at risk in each group at various
intervals is indicated at the bottom of the figure. Results are
expressed as percentage with 95% confidence interval (95% CI).
Primary patency rates at 5 and 10 years were 71.8 10% and 55.6
 12%, respectively in the crossover bypass group compared with
92.7 6% and 82.9 13%, respectively in the direct bypass group
(P  .001, hazard ratio: 4.1 with 95% CI: 1.8 to 6.7).
Table II. Postoperative complications and treatment-relat
Outcome*
Direct bypass
N  69
Postoperative general
complications
5 (7.1%)
Death 1 (1.4%)
Myocardial infarction 1 (1.4%)
Myocardial ischemia 0
Acute respiratory failure 3 (4.3%)
Postoperative femoral
complications
3 (4.3%)
Hematoma 0
Lymphocele 2 (2.9%)
Superficial infection 1 (1.4%)
Graft infection 0
Length of hospitalization (d)† 7 (4-10)
Sexual dysfunction
Erectile dysfunction 2/59 (3.4%)
Ejaculatory disorder 4/59 (6.8%)
Bypass patency at 5 y‡
Primary patency 92.7  6.1%
Assisted primary patency 92.7  6.1%
Secondary patency 97.0  3.0%
Survival at 10 y 59.3  17%
HR, Hazard ratio.
*Proportions, means, and medians were compared using the Fisher exact
respectively.
†Expressed as medians with the interquartile range.
‡Five and 10-year results calculated by the Kaplan-Meier method with 95%
hazard ratio.(n  30) required further revascularization. In 30 casesof primary crossover bypass failure, flow was successfully
maintained or restored by patch placement on the fem-
oral anastomosis in four of four cases, angioplasty of the
Fig 3. Assisted primary patency of the 69 direct and 74 crossover
procedures analyzed according to the Kaplan-Meier method. The
number of patients at risk in each group at various intervals is
indicated at the bottom of the figure. Results are expressed as
percentage with 95% confidence interval (95% CI). Assisted pri-
mary patency rates at 5 and 10 years were 84.3% and 74.8%,
respectively in the crossover bypass group and 92.7% vs 86.1%,
respectively in the direct bypass group (P  .04, hazard ratio: 2.5
with 95% CI: 1.1 to 5.8).
utcomes after direct and crossover bypass
Crossover bypass
N  74 P value
2 (2.6%) .26
0
1 (1.3%)
1 (1.3%)
0
10 (13.4%) .08
4 (5.4%)
4 (5.4%)
1 (1.3%)
1 (1.3%)
4 (2-7) .03
3/67 (4.5%) .95
0/67 (0%) .04
71.8  10% .001 (HR: 4.1)
84.3  8.5% .04 (HR: 2.5)
89.8  7.1% .03 (HR: 3.7)
61.2  9% .59 (HR: 1.2)
tudent t-test, and Kaplan-Meier method with log-rank and hazard ratios,
dence interval method (95% CI) and compared by the log-rank test withed o
test, Sdonor iliac artery in 10 of 12, and thrombectomy of the
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direct bypass failures, patency was successfully restored
or maintained by femoral patch angioplasty in two of two
and by thrombectomy in three of six. Two patients, one
in each group (n  2), required major lower limb
amputation.
Impact of femoral artery run-off on bypass patency.
Patency after crossover and direct bypass was analyzed in
function of SFA run-off in the recipient leg. In the cross-
over bypass group, primary patency rates at five and 10
years were 71.9% and 64.3%, respectively in patients pre-
senting no or low-grade (50%) stenosis of the SFA com-
pared with 62.5% and 42.3%, respectively in patients pre-
senting high-grade stenosis (50) or occlusion of the SFA
(Fig 6). This difference was significant (P  .04, hazard
ratio: 2.0 with 95% CI: 1.04 to 5.0). In the direct bypass
group, primary patency rates were not significantly corre-
lated with SFA run-off with a 10-year patency rate of 95.8%
in patients presenting no or low-grade (50%) stenosis of
the SFA compared with 90.4% in patients presenting high-
grade stenosis (50) or occlusion of the SFA (P  .94,
hazard ratio: 0.98 with 95% CI: 0.2 to 5.8). In this analysis,
SFA run-off was considered as normal in patients who
underwent concomitant infrainguinal revascularization.
Impact of technique and prosthetic material. In the
crossover bypass group, primary patency at 5 years was not
significantly different for polyester and PTFE grafts: 76.2%
vs 65.6%, respectively (P .24, hazard ratio: 0.61 with 95%
CI: 0.29 to 1.37). Similarly in the direct bypass group,
patency at 5 years was comparable for polyester and PTFE
Fig 4. Secondary patency of the 69 direct and 74 crossover
procedures analyzed according to the Kaplan-Meier method. The
number of patients at risk in each group at various intervals is
indicated at the bottom of the figure. Results are expressed as
percentage with 95% confidence interval (95% CI). Secondary
patency rates at 5 and 10 years were 89.8% and 82.9%, respectively
in the crossover bypass group vs 97.0% and 94.9%, respectively in
the direct bypass group (P  .03, hazard ratio: 3.7 with 95% CI:
1.1 to 9.8).grafts: 95.0% vs 89.4% (P  .98, hazard ratio: 0.98 with95% CI: 0.22 to 4.4). Primary patency was not significantly
different between aortofemoral direct bypass and common-
iliac-to-femoral direct bypass or between femorofemoral
crossover bypass and external iliac-to-femoral crossover
bypass. Finally, no significant difference in patency was
observed within each group according to the graft diameter
and patency was comparable for externally supported grafts
and unsupported grafts in the crossover group.
Hemodynamic outcome on the symptomatic side
after direct and crossover bypass. To evaluate hemody-
namic outcome, ABI was measured in the symptomatic leg
before and after revascularization. As shown in Table III,
preoperative and postoperative ABI was comparable in the
two treatment groups, thus, suggesting that the hemody-
namic outcome of direct and crossover bypass was compa-
rable.
Hemodynamic assessment on the donor artery side
after crossover bypass. To study the possible hemody-
namic consequences of crossover bypasses on flow in the
donor iliac artery used as the take-off vessel, ABI was
measured on the donor side before and after crossover
bypass in function of the SFA run-off. As shown in Table
IV, no significant difference was found between preopera-
tive and postoperative ABI on the donor side.
Survival. Patient survival was 94.8% at 5 years and
59.5% at 10 years. Thirty-three patients died during follow-
up. The main causes of death were cardiovascular disease
(n  18) and cancer (n  6). There was no significant
difference in survival between the direct and crossover
bypass groups (P .58, hazard ratio: 1.2 with 95% CI: 0.6
to 2.4).
DISCUSSION
This randomized study shows that primary patency,
assisted primary patency, and secondary patency were sig-
nificantly better after direct bypass than after crossover
bypass. Since progression of atherosclerosis in the donor
artery is a frequent cause of crossover bypass failure, this
study used a strict definition for the end of primary paten-
cy12 that included not only development of significant
stenosis in the crossover bypass graft itself but also in the
contralateral donor iliac artery. The risk of disease progres-
sion in the contralateral donor iliac artery was the main
criteria used by Piotrowski et al18 to indicate aortofemoral
bypass instead of crossover bypass even in young patients.
After a median follow-up of 7.4 years in our study in which
presence of a normal contralateral iliac donor artery was a
condition for inclusion, stenosis in the artery that served or
would have served as the donor artery for crossover bypass,
was observed in 12 patients (16.2%) randomized for cross-
over bypass and in 14 patients (20.2%) randomized for
direct bypass. The high potential for development of sig-
nificant atherosclerotic disease in previously healthy iliac
arteries underlines the need for surveillance using color
flow duplex imaging. In the 12 patients with crossover
bypasses, color flow duplex surveillance allowed detection
of stenosis and restoration of patency by iliac angioplasty.
ease.
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thus a key element for successful crossover bypass. How-
ever, assessment is difficult. Many authors consider angiog-
raphy alone as unreliable.19,20 Archie et al19 stated that
direct measurement of femoral artery pressure at rest and
after injection of papaverine lacked sufficient sensitivity and
specificity for preoperative decision-making. In our study,
normal aspect of the potential donor iliac artery on both
angiography and duplex scan was a prerequisite for inclu-
sion. Although this criterion is arguably overly restrictive,
our intention was to eliminate preoperative status of the
donor iliac artery as a confounding factor for comparison of
direct and crossover bypass. The requirement for a normal
contralateral iliac artery was the main reason that it took 5
years to randomize 143 patients in the 20 surgical centers
participating in this study. Indeed many patients with ex-
tensive unilateral iliac lesions have some form of contralat-
eral iliac disease.
As early as 1973, Porter et al21 acknowledged the
frequency of some degree of contralateral iliac disease in
patients with extensive unilateral iliac disease and became
one of the first groups to recommend use of donor iliac
angioplasty in combination with crossover bypass. Not
surprisingly use of endovascular techniques that can pro-
vide excellent long-term results in selected iliac artery le-
Fig 5. Flowchart representing primary and secondary f
grafts. There were 30 primary failures of crossover bypass
successfully maintained or restored by donor iliac angiop
crossover bypasses and in five failed primary direct bypas
one new crossover femorofemoral graft. Two major a
crossover bypass and unreconstructable distal arterial dissions has improved the outcome of crossover bypass inpatients with a suboptimal donor iliac artery.22-24 The
experience of several authors25-27 has supported this view.
In nonrandomized studies comparing crossover femoral
grafts with or without donor iliac balloon angioplasty, both
Schneider et al25 and Perler et al24 concluded that patency
of the crossover bypass in patients who underwent prelim-
inary stenting of the iliac artery was comparable to that of
patients whose donor iliac artery was normal. These find-
ings clearly support the use of angioplasty with or without
stenting before or at the same time as crossover bypass in
eligible patients with donor iliac lesions. Recently, Abu-
Rahma et al28 reported that successful crossover bypass
after angioplasty was more likely if the dilated iliac lesion
was short and located in the common iliac artery.
Another reported cause of crossover femorofemoral
graft failure is progression of outflow arterial disease in the
recipient limb.4,29,30 In our study, occlusion or significant
stenosis of the SFA in the recipient leg was associated with
significantly lower patency after crossover bypass but not
after direct bypass. However, the clinical value of this
finding is subject to caution because the impact of SFA
status on bypass patency was not a primary endpoint of the
study, and also because of the small size of these subgroups.
Another concern expressed by many investigators
about crossover bypass involves the ability of one iliac artery
s occurring in patients with crossover and direct bypass
ight primary failures of direct bypasses. Arterial flow was
thrombectomy, or femoral patch angioplasty in 20 failed
econdary failures required 10 aortobifemoral grafts and
ations were required in patients with failed direct orailure
and e
lasty,
ses. S
mputto supply blood flow to both legs and the possibility of
8).
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mental model, Ehrenfeld31 was the first to demonstrate
that the flow in the donor iliac artery increased after cross-
over bypass with no reduction in downstream iliac flow.
Sumner and Strandness32 showed that crossover bypass had
no significant deleterious effect on the donor limb and that
the recipient limb was well perfused provided that there was
Fig 6. Primary patency of crossover bypasses and direc
(SFA) run-off in the symptomatic leg. The number of pa
the bottom of the figure. Results are expressed with 95%
primary patency rates at 5 and 10 years were 71.9% and
(50%) stenosis of the SFA compared with 62.5% and 4
(50) or occlusion of the SFA (P .04, hazard ratio: 2.0
patency rates were not significantly correlated with SFA r
no or low-grade stenosis of the SFA compared with 90.4%
SFA (P  .94, hazard ratio: 0.98 with 95% CI: 0.2 to 5.
Table III. Hemodynamic assessment of the
revascularized leg by measurement of the pre- and
postoperative ankle-brachial systolic pressure index (ABI)
in function of superficial femoral artery (SFA) run-off in
the crossover and direct bypass groups
Preoperative ABI Postoperative ABI
SFA
occluded SFA patent
SFA
occluded SFA patent
Crossover
bypass 0.43  0.16 0.56  0.16 0.75  0.17 0.97  0.17
Direct
bypass 0.41  0.15 0.55  0.17 0.72  0.21 1.02  0.15
P value 0.89* 0.82* 0.79† 0.87‡
Results were expressed as means value  standard deviation.
*Comparison of preoperative ABI in function of the SFA run-off did not
show any significant difference in each category between the direct and
crossover bypass groups.
†Comparison of the postoperative ABI between direct and crossover bypass
did not show any significant difference in each category, thus suggesting that
hemodynamic outcome of direct and crossover bypass is comparable.no hemodynamically significant lesion in the donor iliacartery. Our follow-up findings are consistent with these
studies since the only significant ABI reduction observed in
the donor limb after crossover bypass involved the 12
patients who developed stenosis of the donor iliac artery.
Measurement of ABI also enabled us to compare rest-
ing hemodynamics after crossover and direct bypass. This
comparison indicated that the hemodynamic results of the
two procedures were comparable. Literature data on this
point have been contradictory. The Veterans Affairs Coop-
erative Study No 1419 including 340 patients with cross-
over femorofemoral grafts showed significant improvement
in postoperative ABI. Conversely, based on a nonrandom-
ized study comparing direct and crossover bypasses,
Schneider et al25 concluded that resting recipient limb
asses analyzed in function of superficial femoral artery
s at risk in each group at various intervals is indicated at
dence interval (95% CI). In the crossover bypass group,
3%, respectively in patients presenting no or low-grade
, respectively in patients presenting high-grade stenosis
95%CI: 1.04 to 5.0). In the direct bypass group, primary
ff with a 10-year patency of 95.8% in patients presenting
tients presenting high-grade stenosis or occlusion of the
Table IV. Hemodynamic assessment of the donor side in
patients who underwent crossover bypass
Ankle-brachial indices*
P valuePreoperative Postoperative
Patent SFA 1.02  0.14 1.00  0.15 0.89
Occluded SFA 0.72  0.17 0.72  0.21 0.96
SFA, Superficial femoral artery.
Pre- and postoperative mean ABI values on the donor side were compared in
patients undergoing crossover bypass in function of superficial femoral artery
(SFA) lesions. No significant difference was found.
Results were expressed as means value  standard deviation.
*Ankle-brachial indices (ABI) expressed as means  standard deviation.t byp
tient
confi
64.
2.3%
with
un-o
in papressure in patients with crossover bypass was abnormal
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using exercise testing will be needed to settle this issue.
Our results also provide some insight into the impact of
graft material and external support on long-term results of
direct and crossover bypass. Polyester and PTFE grafts
performed equally well in both treatment groups. Though
this finding is subject to bias since choice of type and
diameter of the prosthetic graft was left to the discretion of
the surgeon, it is consistent with two randomized studies
showing no difference in patency outcome using different
graft material for femorofemoral crossover bypass.8,9
Bypass-related complications including graft infection
and seroma formation were also comparable for the two
materials. Like Johnson et al,9 we could not confirm the
findings of one nonrandomized retrospective study33
showing that externally supported grafts provided better
results than unsupported grafts for femorofemoral cross-
over bypass.
The use of different techniques of bypass in the two
patient groups in this study could have had a confounding
effect on the findings of our analysis although it should be
noted that comparable patency was achieved using the two
crossover bypass techniques, ie, from the external iliac
artery or common femoral artery. Similarly no difference in
patency was observed between direct bypass from the aorta
and from the common iliac artery. Based on these observa-
tions, we do not think that the nonhomogeneity of the
groups with regard to surgical techniques had a biasing
effect in our study.
Regarding graft diameter, our results were concordant
with those of Schneider et al25 since there was no significant
difference in patency using 6-, 7-, and 8-mm-diameter
grafts. However, these subgroups were small and, thus,
subject to type 2 error. This study also confirmed the low
general morbidity of crossover bypass. This finding appears
logical since superficial crossover bypass is less invasive than
direct aorto- or iliofemoral bypass even when performed by
a retroperitoneal approach. The absence of a significant
difference in morbidity between the crossover (2.6%) and
direct (7.1%) bypass group in our study is undoubtedly due
to our selection criteria that excluded high-risk patients and
to our relatively small patient population. Local complica-
tions were more frequent in patients undergoing crossover
bypass. This difference was probably due to the fact that 41
of the 74 crossover bypasses were femorofemoral proce-
dures requiring bilateral access to the common femoral
arteries thus doubling the risk of complications in the groin
area.
The results of crossover bypass in this study were con-
cordant with those reported in the literature. Table V
summarizes the results of recent crossover bypass series that
presented 5-year follow-up results using the actuarial or
Kaplan-Meier method. Our long-term follow-up data were
comparable to those reported by Brener et al29 and Criado
et al.26 The good results of unilateral aortofemoral or
iliofemoral direct bypass in our study are also in line with
those reported by Couch et al44 and Kalman et al.45Objective review of data from our study and the litera-
ture indicates that direct iliac revascularization offers the
best long-term patency in patients with extensive unilateral
iliac artery occlusion, but currently with the development
of endovascular technology, this is likely done by interven-
tional techniques.
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Dr George Andros (Encino, Calif). I would like to congratu-
late you not only for presenting a wonderful series but also for
coming to us with 10-year clinical and hemodynamic data. That is
something we must encourage from our colleagues who favor
endovascular techniques and I applaud you for doing that.
I have two questions. In view of the fact that 20% of your patients
developed contralateral occlusive disease after they had an aorto or
iliofemoral bypass, would you recommend that the patients with
extensive unilateral iliac disease undergo primary aortobifemoral by-Second, since the patients with compromised outflow on the
recipient side did less well, would you recommend that they are
watched more closely with a low threshold for receiving a distal
bypass graft? Not only would this policy relieve symptoms but also
preserve the cross femoral bypass.
Dr Jean-Baptiste Ricco. Concerning your first question and
looking at the results of our study, you may be right, however, at
the present time, we will certainly proceed first with an iliac
recanalization or a hybrid procedure with iliac recanalization and
femoral reconstruction. If this does not work, we will then certainly
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ancy of the patient is high. Concerning the femoral outflow,
occlusion or significant stenosis of the SFA in the recipient leg was
associated in our study with a significantly lower patency after
crossover bypass but not after direct bypass, and we will certainly
recommend in these cases a distal revascularization to enhance
patency of the crossover bypass.
Dr Vikram Kashyap (Cleveland, Ohio). Two questions. One,
in our series, looking at endovascular recanalization of iliac occlu-
sions, 30% of groin vessels needed either an endarterectomy or a
profundaplasty. Is that similar in your series?
Second, when this study started 20 years ago, all of these
patients were excluded from endovascular techniques that were
deemed not feasible. But in the end, if I understood correctly,
approximately 16% ended up getting an angioplasty on the ipsilat-
eral iliac artery. Have endovascular techniques changed your ap-
proach to iliac occlusions?
Dr Jean-Baptiste Ricco. Concerning your first question, we
have the same experience, in this series, 52 out of 143 patients
(36%) had a profundaplasty with or without a femoral endarterec-
tory. Considering your second question, we did 12 angioplasties of
the donor iliac artery in the crossover group mainly for TASC A orB lesions that developed some years after construction of the
crossover bypass. In the direct bypass group, 14 patients (20.2%)
developed significant stenosis of the contralateral iliac artery re-
quiring angioplasty in six and crossover bypass in two. Our practice
has certainly changed in the last 10 years. Not surprisingly, endo-
vascular techniques can provide excellent long-term results in
selected iliac artery lesions and have also improved the outcome of
crossover femoral bypass in patients with suboptimal donor iliac
artery.
Dr Subodh Arora (Washington, DC). I noticed that quite a
number of patients in the iliofemoral group, you used the trans-
peritoneal approach. Was there any particular reason why that
approach was used over the retroperitoneal?
Dr Jean-Baptiste Ricco. Two different techniques were used in
the direct bypass group: 36 patients had an aortofemoral bypass
and 33 patients had a common iliac-femoral bypass. Forty-three
patients had a retroperitoneal approach and 26 patients had a
transperitoneal approach. All direct iliofemoral bypasses and 10
aortofemoral bypasses were approached by a retroperitoneal route.
Transperitoneal route was used exclusively in the remaining 26
patients with an aortafemoral bypass. In this study, the choice of
the operative technique was left to the discretion of the surgeon.
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University Hospital Sainte-Marguerite, Marseille (P. Piquet),
Clinique Poirier, Chambery (B. Habozit), University Hospi-tal Pitié Salpêtrière, Paris (E. Kieffer, F. Koskas), Hôpital
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